Business and Finance

Acquisition of 86,000 square-foot plant has capability of manufacturing 1.8 billion capsules annually

Deal helps expands software company’s labeling capabilities in clinical trial, med device and pharma spaces

Protagen, BioAnalytix and GeneWerk merger set to target biopharma, C&GT sectors

Tufts analysis uncovers various benefits to conducting decentralized clinical trials—including financial benefits

Acquisition of AcKnowledge RS also expands company's IVD expertise

Partnership enhances CBM’s manufacturing capabilities in C&GT space

Syneos Health’s annual survey reveals the potential for shifts in the M&A space

Marks the first step in two-phase facility expansion project

Collaboration aims to prioritize best practices in fields of biopreservation and closed-system manufacturing, while improving children’s health

The shot—which could be the first one to be mRNA based—is scheduled to begin clinical trials later this year

Development project features 150,000 square feet of additional space to accommodate company’s 3PL offerings

Investment features the construction of a high-throughput screening center

BFS technology deal expected to be finalized in Q1

Deal expands GE’s $3 billion ultrasound business from diagnostics into surgical and therapeutic interventions

Firms will merge under the CSafe brand, allowing for delivery of temperature-sensitive items

ABC’s new acquisition, FirstView Financial, addresses underpayment of pharmacies, as well as patient assistance programs

Purchase of Engage grows the company’s knowledge in the data and analytics space

Deal expands pharma giant’s influence in inflammation and immunology markets

The $17.4-billion deal, CDMO says, will help expand its offerings in the clinical development space

Via investment partnership with Taishin Holdings, will begin offering manufacturing services in C&GT space

Upon deal completion, group will acquire company’s oncology product portfolio for $846 million

CDMO’s financial commitment will feature construction of a new GMP clinical trial development facility

Financial commitment is predicted to more than double the biopharma site’s manufacturing capabilities

Transaction expands CDMO’s services, including more solutions surrounding commercial manufacturing

Five-year deal covers manufacturing of molecules, ranging from monoclonal antibodies to antibody-drug conjugates

Subject to regulatory approval, CDMO will produce mRNA vaccine on a commercial scale

The Discovery Centre will be powered by AI technology, robotics, among other features

Transaction is anticipated to further Novo’s research in the field of RNAi therapeutics

Acquisition of biopharma company features sotatercept, which is in Phase III trials for the treatment of pulmonary arterial hypertension

Financial commitment expected to increase plant's process development and manufacturing capacity